TriangleLABELS · c109ab9f-879a-4e37-b6ff-10a027779522
Adalimumab-ryvk
Open original source → · Download preserved record
Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.
- Label effective date
- 2026-03-03
- Captured
- 2026-09-09T23:37:58.719708+00:00
- Current indication reconciliation
- Not reconciled
Boxed warning in this label
- WARNING: SERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with adalimumab products, including Adalimumab-ryvk, are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 )] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue Adalimumab-ryvk if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before Adalimumab-ryvk use and during therapy. Initiate treatment for latent TB prior to Adalimumab-ryvk use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. Carefully consider the risks and benefits of treatment with Adalimumab-ryvk prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with Adalimumab-ryvk, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )] . MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products [see Warnings and Precautions ( 5.2 )] . Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6-MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions ( 5.2 )] . WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning. SERIOUS INFECTIONS ( 5.1 , 6.1 ): Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Discontinue Adalimumab-ryvk if a patient develops a serious infection or sepsis during treatment. Perform test for latent TB; if positive, start treatment for TB prior to starting Adalimumab-ryvk. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. MALIGNANCY ( 5.2 ): Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including adalimumab products.
Indications and usage: exact source text
- 1 INDICATIONS AND USAGE Adalimumab-ryvk is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older ( 1.9 ) 1.1 Rheumatoid Arthritis Adalimumab-ryvk is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Adalimumab-ryvk can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis Adalimumab-ryvk is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Adalimumab-ryvk can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis Adalimumab-ryvk is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Adalimumab-ryvk can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis Adalimumab-ryvk is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn’s Disease Adalimumab-ryvk is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis Adalimumab-ryvk is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 )] . 1.7 Plaque Psoriasis Adalimumab-ryvk is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Adalimumab-ryvk should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 )] . 1.8 Hidradenitis Suppurativa Adalimumab-ryvk is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis Adalimumab-ryvk is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
Full extracted label fields
- application numbers
- BLA761299
- boxed warning exact
- WARNING: SERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with adalimumab products, including Adalimumab-ryvk, are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 )] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue Adalimumab-ryvk if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before Adalimumab-ryvk use and during therapy. Initiate treatment for latent TB prior to Adalimumab-ryvk use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. Carefully consider the risks and benefits of treatment with Adalimumab-ryvk prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with Adalimumab-ryvk, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )] . MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products [see Warnings and Precautions ( 5.2 )] . Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6-MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions ( 5.2 )] . WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning. SERIOUS INFECTIONS ( 5.1 , 6.1 ): Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Discontinue Adalimumab-ryvk if a patient develops a serious infection or sepsis during treatment. Perform test for latent TB; if positive, start treatment for TB prior to starting Adalimumab-ryvk. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. MALIGNANCY ( 5.2 ): Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including adalimumab products.
- brand names
- Adalimumab-ryvk
- current indication status
- not_reconciled
- dailymed set url
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- generic names
- ADALIMUMAB-RYVK
- id
- c109ab9f-879a-4e37-b6ff-10a027779522
- indications and usage exact
- 1 INDICATIONS AND USAGE Adalimumab-ryvk is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older ( 1.9 ) 1.1 Rheumatoid Arthritis Adalimumab-ryvk is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Adalimumab-ryvk can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis Adalimumab-ryvk is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Adalimumab-ryvk can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis Adalimumab-ryvk is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Adalimumab-ryvk can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis Adalimumab-ryvk is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn’s Disease Adalimumab-ryvk is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis Adalimumab-ryvk is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 )] . 1.7 Plaque Psoriasis Adalimumab-ryvk is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Adalimumab-ryvk should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 )] . 1.8 Hidradenitis Suppurativa Adalimumab-ryvk is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis Adalimumab-ryvk is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
- indications and usage tables exact
- is original packager
- true
- manufacturer names
- Teva Pharmaceuticals USA, Inc.
- matched search terms
- tumor
- package ndcs
- 51759-310-59
- 51759-312-30
- 65517-0002-1
- 51759-311-58
- 51759-313-30
- product ndcs
- 51759-310
- 51759-311
- product types
- HUMAN PRESCRIPTION DRUG
- recent major changes exact
- Indications and Usage, Hidradenitis Suppurativa (1.8) 10/2025 Indications and Usage, Uveitis (1.9) 10/2025 Dosage and Administration, Recommended Dosage in Juvenile Idiopathic Arthritis or Pediatric Uveitis (2.3) 10/2025 Dosage and Administration, Recommended Dosage in Hidradenitis Suppurativa (2.7) 10/2025 Warnings and Precautions, Autoimmunity (5.9) 10/2025 Indications and Usage, Hidradenitis Suppurativa ( 1.8 ) 10/2025 Indications and Usage, Uveitis ( 1.9 ) 10/2025 Dosage and Administration, Recommended Dosage in Juvenile Idiopathic Arthritis or Pediatric Uveitis ( 2.3 ) 10/2025 Dosage and Administration, Recommended Dosage in Hidradenitis Suppurativa ( 2.7 ) 10/2025 Warnings and Precautions, Autoimmunity ( 5.9 ) 10/2025
- record type
- complete_spl_indications_section_candidate
- routes
- rxcuis
- 797544
- 2677780
- 2706644
- source batch
- file
- /private/tmp/cancer-full-research/indications/raw/labels-00600.json
- meta
- disclaimer
- Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
- last updated
- 2026-09-09
- results
- limit
- 100
- skip
- 600
- total
- 830
- sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl effective time
- 20260303
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- substance names
- uniis
- verification flags
- oncology_keyword_candidate_not_clinically_classified
- spl_text_not_verified_identical_to_latest_approved_label
- individual_indications_not_split_or_reconciled
Drugs@FDA application source records
- application number
- BLA761299
- payload
- all indexed label documents
- Appl No
- 761299
- Application Docs Date
- 2024-02-23 00:00:00
- Application Docs ID
- 77620
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761299s000lbl.pdf
- Submission No
- 1
- Submission Type
- ORIG
- Appl No
- 761299
- Application Docs Date
- 2024-06-04 00:00:00
- Application Docs ID
- 78622
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761299s001lbl.pdf
- Submission No
- 1
- Submission Type
- SUPPL
- Appl No
- 761299
- Application Docs Date
- 2024-08-29 00:00:00
- Application Docs ID
- 79498
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761299s003s006lbl.pdf
- Submission No
- 3
- Submission Type
- SUPPL
- Appl No
- 761299
- Application Docs Date
- 2024-08-29 00:00:00
- Application Docs ID
- 79499
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761299s003s006lbl.pdf
- Submission No
- 6
- Submission Type
- SUPPL
- Appl No
- 761299
- Application Docs Date
- 2025-02-18 00:00:00
- Application Docs ID
- 81266
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761299s016lbl.pdf
- Submission No
- 16
- Submission Type
- SUPPL
- Appl No
- 761299
- Application Docs Date
- 2025-04-08 00:00:00
- Application Docs ID
- 81842
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761299s013s020lbl.pdf
- Submission No
- 13
- Submission Type
- SUPPL
- Appl No
- 761299
- Application Docs Date
- 2025-04-08 00:00:00
- Application Docs ID
- 81843
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761299s013s020lbl.pdf
- Submission No
- 20
- Submission Type
- SUPPL
- Appl No
- 761299
- Application Docs Date
- 2025-10-21 00:00:00
- Application Docs ID
- 83836
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761299s025lbl.pdf
- Submission No
- 25
- Submission Type
- SUPPL
- Appl No
- 761299
- Application Docs Date
- 2025-11-07 00:00:00
- Application Docs ID
- 84129
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761299s024lbl.pdf
- Submission No
- 24
- Submission Type
- SUPPL
- all submission records
- Appl No
- 761299
- Review Priority
- STANDARD
- Submission Class Code ID
- 19
- Submission No
- 1
- Submission Status
- AP
- Submission Status Date
- 2024-02-23 00:00:00
- Submission Type
- ORIG
- Submissions Public Notes
- Appl No
- 761299
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 1
- Submission Status
- AP
- Submission Status Date
- 2024-05-31 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 761299
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 3
- Submission Status
- AP
- Submission Status Date
- 2024-08-26 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 761299
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 6
- Submission Status
- AP
- Submission Status Date
- 2024-08-26 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 761299
- Review Priority
- N/A
- Submission Class Code ID
- 4
- Submission No
- 7
- Submission Status
- AP
- Submission Status Date
- 2024-06-26 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 761299
- Review Priority
- STANDARD
- Submission Class Code ID
- 4
- Submission No
- 13
- Submission Status
- AP
- Submission Status Date
- 2025-04-07 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 761299
- Review Priority
- N/A
- Submission Class Code ID
- 4
- Submission No
- 16
- Submission Status
- AP
- Submission Status Date
- 2025-02-14 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 761299
- Review Priority
- N/A
- Submission Class Code ID
- 4
- Submission No
- 20
- Submission Status
- AP
- Submission Status Date
- 2025-04-07 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 761299
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 24
- Submission Status
- AP
- Submission Status Date
- 2025-11-06 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 761299
- Review Priority
- Submission Class Code ID
- 28
- Submission No
- 25
- Submission Status
- AP
- Submission Status Date
- 2025-10-16 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- application number
- BLA761299
- approval interpretation
- Application linkage and approved submission are not indication-level current approval verification
- current indication status
- not_reconciled
- drugsfda url
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761299
- has approved submission record
- true
- latest approved submission date
- 2025-11-06
- latest label selection rule
- max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
- latest posted label documents
- Appl No
- 761299
- Application Docs Date
- 2025-11-07 00:00:00
- Application Docs ID
- 84129
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761299s024lbl.pdf
- Submission No
- 24
- Submission Type
- SUPPL
- official application record
- Appl No
- 761299
- Appl Public Notes
- Appl Type
- BLA
- Sponsor Name
- ALVOTECH USA INC
- openfda application present
- true
- products
- Active Ingredient
- ADALIMUMAB-RYVK
- Appl No
- 761299
- Drug Name
- SIMLANDI
- Form
- INJECTABLE;INJECTION
- Product No
- 001
- Reference Drug
- 0
- Reference Standard
- 0
- Strength
- 40MG/0.4ML
- marketing status
- Prescription
Source passages and status connections
Passage 1 · positive indication candidate
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 515
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE Adalimumab-ryvk is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 0
- current approval status
- not_reconciled
- duplicate text group
- dup-130f3ff6977bf1d8a295
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-a4475c30c41c1cc82aab
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- end
- 90
- end exclusive
- true
- exact text
- is a tumor necrosis factor (TNF) blocker indicated
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 40
- qualifier mentions
- context exact
- on of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis .
- kind
- age
- polarity
- not_inferred
- span
- end
- 257
- end exclusive
- true
- exact text
- adult patients
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 243
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 315
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE Adalimumab-ryvk is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis .
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 0
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 2 · unclassified context
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 666
- end exclusive
- true
- exact text
- ymptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and sy
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 116
- current approval status
- not_reconciled
- duplicate text group
- dup-1afd0b94c1f46a4ab657
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-a221a1a1c275bd0f2e06
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- ive polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
- kind
- age
- polarity
- not_inferred
- span
- end
- 455
- end exclusive
- true
- exact text
- 2 years of age
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 441
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 466
- end exclusive
- true
- exact text
- ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 316
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 3 · positive indication candidate
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 836
- end exclusive
- true
- exact text
- rately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 267
- current approval status
- not_reconciled
- duplicate text group
- dup-1869d16df132a287d3f9
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-c80aa41c15d9ab96a294
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- end
- 90
- end exclusive
- true
- exact text
- is a tumor necrosis factor (TNF) blocker indicated
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 40
- qualifier mentions
- context exact
- on of structural damage, and improving physical function in adult patients with active psoriatic arthritis .
- kind
- age
- polarity
- not_inferred
- span
- end
- 602
- end exclusive
- true
- exact text
- adult patients
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 588
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 636
- end exclusive
- true
- exact text
- ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis .
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 467
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 4 · positive indication candidate
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 927
- end exclusive
- true
- exact text
- nts 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 437
- current approval status
- not_reconciled
- duplicate text group
- dup-205eac0a3f77ef2f3ea8
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-ceea0e2db9efb050850a
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- end
- 90
- end exclusive
- true
- exact text
- is a tumor necrosis factor (TNF) blocker indicated
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 40
- qualifier mentions
- context exact
- ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis .
- kind
- age
- polarity
- not_inferred
- span
- end
- 690
- end exclusive
- true
- exact text
- adult patients
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 676
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 727
- end exclusive
- true
- exact text
- ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis .
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 637
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 5 · positive indication candidate
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 1053
- end exclusive
- true
- exact text
- on of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or we
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 528
- current approval status
- not_reconciled
- duplicate text group
- dup-9302dd8b9cc305adb5a4
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-70ca294db88270739c41
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- end
- 90
- end exclusive
- true
- exact text
- is a tumor necrosis factor (TNF) blocker indicated
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 40
- qualifier mentions
- context exact
- eatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
- kind
- age
- polarity
- not_inferred
- span
- end
- 804
- end exclusive
- true
- exact text
- adults
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 798
- context exact
- moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
- kind
- age
- polarity
- not_inferred
- span
- end
- 827
- end exclusive
- true
- exact text
- pediatric patients
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 809
- context exact
- ely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
- kind
- age
- polarity
- not_inferred
- span
- end
- 842
- end exclusive
- true
- exact text
- 6 years of age
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 828
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 853
- end exclusive
- true
- exact text
- ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 728
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 6 · unclassified context
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1142
- end exclusive
- true
- exact text
- signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chroni
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 654
- current approval status
- not_reconciled
- duplicate text group
- dup-e7c711671584ae282081
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-8e4f25e0cbf98e096a20
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- ment of moderately to severely active ulcerative colitis in adult patients.
- kind
- age
- polarity
- not_inferred
- span
- end
- 941
- end exclusive
- true
- exact text
- adult patients
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 927
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 942
- end exclusive
- true
- exact text
- ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients.
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 854
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 7 · limitation of use
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 1283
- end exclusive
- true
- exact text
- nt of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 743
- current approval status
- not_reconciled
- duplicate text group
- dup-2d8e4b15d1d502cbdbcc
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-4e9ddf88f51e0f30f347
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 1083
- end exclusive
- true
- exact text
- ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers.
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 943
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 8 · unclassified context
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1483
- end exclusive
- true
- exact text
- y to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediat
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 884
- current approval status
- not_reconciled
- duplicate text group
- dup-0f933540d6cdee920131
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-7c65395298b0116f947a
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- Treatment of adult patients with moderate to severe chronic plaque psoriasis who are ca
- kind
- age
- polarity
- not_inferred
- span
- end
- 1111
- end exclusive
- true
- exact text
- adult patients
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 1097
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 1283
- end exclusive
- true
- exact text
- Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 1084
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 9 · unclassified context
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1728
- end exclusive
- true
- exact text
- Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older ( 1.9 ) 1.1 Rheumatoid Arthritis Adalimumab-ryvk is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical functi
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 1084
- current approval status
- not_reconciled
- duplicate text group
- dup-36be8b6ae1f0364d0841
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-6cebff0a7a40415cf53c
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- of moderate to severe hidradenitis suppurativa in patients 12 years of age and older ( 1.8 ) Treatment of non-infectious intermediate,
- kind
- age
- polarity
- not_inferred
- span
- end
- 1376
- end exclusive
- true
- exact text
- 12 years of age
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 1361
- context exact
- f non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older ( 1.9 )
- kind
- age
- polarity
- not_inferred
- span
- end
- 1472
- end exclusive
- true
- exact text
- adults
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 1466
- context exact
- tious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older ( 1.9 )
- kind
- age
- polarity
- not_inferred
- span
- end
- 1495
- end exclusive
- true
- exact text
- pediatric patients
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 1477
- context exact
- posterior, and panuveitis in adults and pediatric patients 2 years of age and older ( 1.9 )
- kind
- age
- polarity
- not_inferred
- span
- end
- 1510
- end exclusive
- true
- exact text
- 2 years of age
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 1496
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 1528
- end exclusive
- true
- exact text
- ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older ( 1.9 )
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 1284
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 10 · positive indication candidate
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 2005
- end exclusive
- true
- exact text
- denitis suppurativa in patients 12 years of age and older ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older ( 1.9 ) 1.1 Rheumatoid Arthritis Adalimumab-ryvk is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Adalimumab-ryvk can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis Adalimumab-ryvk is indic
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 1329
- current approval status
- not_reconciled
- duplicate text group
- dup-d0fcafa91baee502db04
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-b5758dd761819a6c36e2
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- end
- 1582
- end exclusive
- true
- exact text
- is indicated
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 1570
- qualifier mentions
- context exact
- on of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
- kind
- age
- polarity
- not_inferred
- span
- end
- 1748
- end exclusive
- true
- exact text
- adult patients
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 1734
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 1805
- end exclusive
- true
- exact text
- 1.1 Rheumatoid Arthritis Adalimumab-ryvk is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 1529
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 11 · unclassified context
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2146
- end exclusive
- true
- exact text
- symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. Adalimumab-ryvk can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis Adalimumab-ryvk is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 1606
- current approval status
- not_reconciled
- duplicate text group
- dup-9723bd3de4e3c698fa43
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-0dea27760760750db939
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- Adalimumab-ryvk can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1906
- end exclusive
- true
- exact text
- methotrexate or other non-biologic disease-
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 1863
- context exact
- Adalimumab-ryvk can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 1945
- end exclusive
- true
- exact text
- in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs)
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 1843
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 1946
- end exclusive
- true
- exact text
- Adalimumab-ryvk can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 1806
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 12 · positive indication candidate
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 2356
- end exclusive
- true
- exact text
- s with moderately to severely active rheumatoid arthritis. Adalimumab-ryvk can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis Adalimumab-ryvk is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Adalimumab-ryvk can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis Adalimumab-ryvk is indicated for reducing signs and symptoms, inhibiting the progression of structural d
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 1747
- current approval status
- not_reconciled
- duplicate text group
- dup-be40bdeda58f903eade3
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-3ebef161a082e6d35499
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- end
- 2009
- end exclusive
- true
- exact text
- is indicated
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 1997
- qualifier mentions
- context exact
- ive polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
- kind
- age
- polarity
- not_inferred
- span
- end
- 2145
- end exclusive
- true
- exact text
- 2 years of age
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2131
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 2156
- end exclusive
- true
- exact text
- 1.2 Juvenile Idiopathic Arthritis Adalimumab-ryvk is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 1947
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 13 · unclassified context
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2427
- end exclusive
- true
- exact text
- le Idiopathic Arthritis Adalimumab-ryvk is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Adalimumab-ryvk can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis Adalimumab-ryvk is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active ps
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 1957
- current approval status
- not_reconciled
- duplicate text group
- dup-28008bb985b3d97a258c
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-8019ab4c7fa5dd74b48c
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- Adalimumab-ryvk can be used alone or in combination with methotrexate.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 2226
- end exclusive
- true
- exact text
- methotrexate
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2214
- context exact
- Adalimumab-ryvk can be used alone or in combination with methotrexate.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 2226
- end exclusive
- true
- exact text
- in combination with methotrexate
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2194
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 2227
- end exclusive
- true
- exact text
- Adalimumab-ryvk can be used alone or in combination with methotrexate.
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2157
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 14 · positive indication candidate
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 2645
- end exclusive
- true
- exact text
- and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Adalimumab-ryvk can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis Adalimumab-ryvk is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Adalimumab-ryvk can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis Adalimumab-ryvk is indicated for reducing signs and symptoms in adult patients with active ank
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2028
- current approval status
- not_reconciled
- duplicate text group
- dup-84a15feaf05efed9c7c6
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-226008af4547a5687fcc
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- end
- 2280
- end exclusive
- true
- exact text
- is indicated
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2268
- qualifier mentions
- context exact
- on of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
- kind
- age
- polarity
- not_inferred
- span
- end
- 2412
- end exclusive
- true
- exact text
- adult patients
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2398
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 2445
- end exclusive
- true
- exact text
- 1.3 Psoriatic Arthritis Adalimumab-ryvk is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2228
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 15 · unclassified context
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2723
- end exclusive
- true
- exact text
- ritis Adalimumab-ryvk is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Adalimumab-ryvk can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis Adalimumab-ryvk is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn’s Disease Adalimumab-ryvk is indicated for the
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2246
- current approval status
- not_reconciled
- duplicate text group
- dup-eb0650c0c2647c1b6f3d
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-e9da72fe0dbb0f305c17
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- Adalimumab-ryvk can be used alone or in combination with non-biologic DMARDs.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 2522
- end exclusive
- true
- exact text
- in combination with non-biologic DMARDs
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2483
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 2523
- end exclusive
- true
- exact text
- Adalimumab-ryvk can be used alone or in combination with non-biologic DMARDs.
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2446
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 16 · positive indication candidate
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 2865
- end exclusive
- true
- exact text
- the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Adalimumab-ryvk can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis Adalimumab-ryvk is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn’s Disease Adalimumab-ryvk is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis A
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2324
- current approval status
- not_reconciled
- duplicate text group
- dup-2a465e690fbd0f81b184
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-fb0001cccf4850603553
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- end
- 2579
- end exclusive
- true
- exact text
- is indicated
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2567
- qualifier mentions
- context exact
- imumab-ryvk is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
- kind
- age
- polarity
- not_inferred
- span
- end
- 2629
- end exclusive
- true
- exact text
- adult patients
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2615
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 2665
- end exclusive
- true
- exact text
- 1.4 Ankylosing Spondylitis Adalimumab-ryvk is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2524
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 17 · positive indication candidate
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 3040
- end exclusive
- true
- exact text
- be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis Adalimumab-ryvk is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn’s Disease Adalimumab-ryvk is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis Adalimumab-ryvk is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab product
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2466
- current approval status
- not_reconciled
- duplicate text group
- dup-d9c34e69bac401e42dbc
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-127b49259da4151e1500
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- end
- 2714
- end exclusive
- true
- exact text
- is indicated
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2702
- qualifier mentions
- context exact
- eatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
- kind
- age
- polarity
- not_inferred
- span
- end
- 2791
- end exclusive
- true
- exact text
- adults
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2785
- context exact
- moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
- kind
- age
- polarity
- not_inferred
- span
- end
- 2814
- end exclusive
- true
- exact text
- pediatric patients
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2796
- context exact
- ely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
- kind
- age
- polarity
- not_inferred
- span
- end
- 2829
- end exclusive
- true
- exact text
- 6 years of age
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2815
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 2840
- end exclusive
- true
- exact text
- 1.5 Crohn’s Disease Adalimumab-ryvk is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2666
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 18 · positive indication candidate
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 3181
- end exclusive
- true
- exact text
- ankylosing spondylitis. 1.5 Crohn’s Disease Adalimumab-ryvk is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis Adalimumab-ryvk is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 )] . 1.7 Pla
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2641
- current approval status
- not_reconciled
- duplicate text group
- dup-d74901570a8b8c7e99c1
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-f98153e49467073ea8ab
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- end
- 2892
- end exclusive
- true
- exact text
- is indicated
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2880
- qualifier mentions
- context exact
- ment of moderately to severely active ulcerative colitis in adult patients.
- kind
- age
- polarity
- not_inferred
- span
- end
- 2980
- end exclusive
- true
- exact text
- adult patients
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2966
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 2981
- end exclusive
- true
- exact text
- 1.6 Ulcerative Colitis Adalimumab-ryvk is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients.
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2841
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 19 · limitation of use
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 3373
- end exclusive
- true
- exact text
- in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis Adalimumab-ryvk is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 )] . 1.7 Plaque Psoriasis Adalimumab-ryvk is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and whe
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2782
- current approval status
- not_reconciled
- duplicate text group
- dup-65cccb9bb895f9409dd7
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-d47dee2739cee410c9c3
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 3173
- end exclusive
- true
- exact text
- Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 )] .
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2982
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 20 · positive indication candidate
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 3631
- end exclusive
- true
- exact text
- tients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 )] . 1.7 Plaque Psoriasis Adalimumab-ryvk is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Adalimumab-ryvk should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 )] . 1.8 Hidradenitis Suppur
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 2974
- current approval status
- not_reconciled
- duplicate text group
- dup-17290188c27988d38b35
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-614a004e6c0c82ab2c0b
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- end
- 3223
- end exclusive
- true
- exact text
- is indicated
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 3211
- qualifier mentions
- context exact
- Psoriasis Adalimumab-ryvk is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are ca
- kind
- age
- polarity
- not_inferred
- span
- end
- 3259
- end exclusive
- true
- exact text
- adult patients
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 3245
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 3431
- end exclusive
- true
- exact text
- 1.7 Plaque Psoriasis Adalimumab-ryvk is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 3174
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 21 · risk or warning
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- risk_or_warning_words_without_positive_predicate
- clinical review status
- pending
- content role
- risk_or_warning
- context span
- end
- 3807
- end exclusive
- true
- exact text
- treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Adalimumab-ryvk should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 )] . 1.8 Hidradenitis Suppurativa Adalimumab-ryvk is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis Adalimumab-ryvk is indica
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 3232
- current approval status
- not_reconciled
- duplicate text group
- dup-7b399ec00c01df4ad4a6
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-54d9d05b095c030769d6
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 3607
- end exclusive
- true
- exact text
- Adalimumab-ryvk should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 )] .
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 3432
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 22 · positive indication candidate
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 3945
- end exclusive
- true
- exact text
- cally less appropriate. Adalimumab-ryvk should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 )] . 1.8 Hidradenitis Suppurativa Adalimumab-ryvk is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis Adalimumab-ryvk is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 3408
- current approval status
- not_reconciled
- duplicate text group
- dup-061562dd7b3e81492f1e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-a0a2d964a5ba7d20fa79
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- end
- 3665
- end exclusive
- true
- exact text
- is indicated
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 3653
- qualifier mentions
- context exact
- of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
- kind
- age
- polarity
- not_inferred
- span
- end
- 3758
- end exclusive
- true
- exact text
- 12 years of age
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 3743
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 3769
- end exclusive
- true
- exact text
- 1.8 Hidradenitis Suppurativa Adalimumab-ryvk is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 3608
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 23 · positive indication candidate
- application numbers
- BLA761299
- brand names
- Adalimumab-ryvk
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 3945
- end exclusive
- true
- exact text
- see Warnings and Precautions ( 5 )] . 1.8 Hidradenitis Suppurativa Adalimumab-ryvk is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis Adalimumab-ryvk is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 3570
- current approval status
- not_reconciled
- duplicate text group
- dup-27ce54993f5c098d4ca9
- extraction review status
- automated_candidate_pending_source_review
- generic names
- ADALIMUMAB-RYVK
- id
- ind-span-d29fdc8f21e91a55adb8
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- positive predicate support span
- end
- 3810
- end exclusive
- true
- exact text
- is indicated
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 3798
- qualifier mentions
- context exact
- f non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
- kind
- age
- polarity
- not_inferred
- span
- end
- 3896
- end exclusive
- true
- exact text
- adults
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 3890
- context exact
- tious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
- kind
- age
- polarity
- not_inferred
- span
- end
- 3919
- end exclusive
- true
- exact text
- pediatric patients
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 3901
- context exact
- posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
- kind
- age
- polarity
- not_inferred
- span
- end
- 3934
- end exclusive
- true
- exact text
- 2 years of age
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 3920
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source defined aliases
- source span
- end
- 3945
- end exclusive
- true
- exact text
- 1.9 Uveitis Adalimumab-ryvk is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
- label id
- c109ab9f-879a-4e37-b6ff-10a027779522
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 88871d72a10159bab39620d24651fadba957a92aeb0632a5bfb2bcc39c1c42b8
- start
- 3770
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22c109ab9f-879a-4e37-b6ff-10a027779522%22
- spl effective date
- 2026-03-03
- spl set id
- f8c0d3c2-b5ed-4bb8-927c-5c5529343ee6
- spl version
- 1
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Preserved source evidence · Not medical advice